ClinicalTrials.gg
RecruitingNCT07465393exerciseUpdated Mar 12, 2026

Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors

An interventional study of Multimodal Resistance and Relaxation Training and Home-Based Resistance Exercise Training in Breast Neoplasms and Sarcopenia, sponsored by Valeria Chiu. Recruiting at 1 site in Taiwan. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Valeria Chiu · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 380 studies in Breast Neoplasms with a site in Taiwan — 68 open to participants now, 133 under way, 60 of them phase 3. Breast Neoplasms · Taiwan.

Planned enrollment
254th of 332
66 · median 222
Started
2026
with 13 others
No phase
73 of 380
22 open now
Primary completion
2027-04
later than 76 of 132 live
Registered
362nd of 380
by date

Among the 380 studies in Breast Neoplasms with a site in Taiwan, this one is the 254th largest by planned enrollment of the 332 interventional ones that give a count, is one of 14 that started in 2026, is one of 73 with no phase, reaches primary completion later than 76 of the 132 other live ones, and was the 362nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

68 of the 380 studies in Breast Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

62 more — sign in →

All 68 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 380 studies in Breast Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

This study evaluates the comparative effectiveness of a multi-modal facility-based rehabilitation program (therapist-led resistance exercise and relaxation training) versus a self-directed home-based resistance exercise program in post-treatment breast cancer survivors. Participants in both intervention groups will complete a 16-week program consisting of two exercise sessions per week.The multimodal, therapist-led approach is hypothesized to result in superior improvements in physical performance and quality of life outcomes compared to self-directed home exercise

Read the detailed description

Breast cancer treatments, including chemotherapy and radiotherapy, are associated with sarcopenia, a loss of muscle mass and strength, which increases toxicity, surgical complications, and mortality risk. While resistance exercise is known to mitigate muscle loss, the synergistic effect of adding relaxation techniques to address the psychological and neuromuscular tension of cancer treatment is not well established. This study investigates the comparative effectiveness of a multi-modal, facility-based program (elastic band resistance exercise combined with progressive muscle relaxation) versus a self-directed home-based elastic band resistance exercise program. The supervised, multi-modal intervention is hypothesized to offer superior results in muscle mass, physical performance, and quality of life compared to isolated resistance training.

03

Conditions studied

  • Breast Neoplasms
  • Sarcopenia

Keywords

  • Elastic Band Resistance Training
  • Progressive Muscle Relaxation
  • Breast Cancer Survivors
  • Sarcopenia
  • Quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed primary breast cancer
  • Stage I-III non- breast cancer following lumpectomy or mastectomy
  • Completed chemotherapy (with or without radiotherapy)
  • Age ≥ 18 years
  • Able to understand and follow the study protocol
  • Willingness to attend facility-based exercise training.

Exclusion criteria

Exclusion Criteria:

  • (Stage IV) breast cancer
  • Morbid obesity ( > 40 kg/m²)
  • Uncontrolled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 99 mmHg)
  • Presence of implantable medical devices (e.g., pacemakers, nerve stimulators)
  • Presence of metallic surgical implants (e.g., total hip or knee replacements) that interfere with assessment devices
  • for resistance training (e.g., acute infectious disease, severe cardiac disease, severe respiratory insufficiency)
  • Concurrent malignant diseases
  • Current participation in intense systematic exercise training (defined as at least 1 hour, twice per week)
  • Previous participation in an exercise intervention clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Facility-Based Resistance and Relaxation

    Participants engage in a 16-week multimodal rehabilitation program at Taipei Tzu Chi Hospital. The intervention is comprised of one weekly therapist-led session and one weekly self-directed home session (totaling two sessions per week) involving elastic band resistance exercise and relaxation training

    Behavioral: Multimodal Resistance and Relaxation Training

  • Active comparator
    Home-Based Resistance Exercise

    Participants perform a 16-week self-directed elastic band resistance exercise program. The intervention consists of two weekly home-based sessions using elastic bands, performed without therapist supervision.

    Behavioral: Home-Based Resistance Exercise Training

Interventions

  • BehavioralMultimodal Resistance and Relaxation Training

    A 16-week multimodal program consisting of resistance exercise and relaxation training. Participants undergo two sessions per week: one weekly session is conducted under the supervision of a physical therapist at Taipei Tzu Chi Hospital, and one weekly session is self-directed and performed by the participant in a home setting. The resistance exercise portion utilizes progressive elastic band training

  • BehavioralHome-Based Resistance Exercise Training

    A 16-week self-directed resistance exercise program. The intervention consists of two sessions per week performed independently by the participant in a home setting. The exercise regimen utilizes progressive elastic band training and is conducted without direct therapist supervision

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Skeletal Muscle Mass Index (SMI)

    Skeletal Muscle Mass Index (SMI) is calculated by dividing total skeletal muscle mass (kg), as measured by bioelectrical impedance analysis (ACCUNIQ BC720; SELVAS Healthcare), by the square of the height (m²). Higher scores indicate greater muscle mass relative to height (better outcome).

    Time frame: 16 weeks

Secondary outcomes

  1. Functional Battery: Change from Baseline in Handgrip Strength

    Handgrip strength of the dominant hand measured using a hydraulic dynamometer (LiTE - 200 lb Capacity, USA); the highest of three trials is reported. Higher scores indicate greater upper extremity strength (better outcome).

    Time frame: 16 weeks

  2. Functional Battery: Change from Baseline in 4-Meter Gait Speed

    4-meter gait speed (m/s) measured using a standardized timed walk test. Higher scores indicate faster walking speed (better outcome).

    Time frame: 16 weeks

  3. Functional Battery: Change from Baseline in Timed Up & Go (TUG) Test

    Functional mobility and balance measured using the Timed Up \& Go (TUG) test; time recorded in seconds. Higher scores (longer time taken) indicate poorer functional mobility and balance (worse outcome).

    Time frame: 16 weeks

  4. Functional Battery: Change from Baseline in 30-Second Chair Stand Test

    Lower extremity functional strength measured as the total number of stands completed in 30 seconds.

    Time frame: 16 weeks

  5. Body Composition: Change from Baseline in Body Fat Mass

    Body fat mass (kg) measured using bioelectrical impedance analysis (ACCUNIQ BC720; SELVAS Healthcare). Higher scores indicate greater absolute body fat (worse outcome in the context of sarcopenia/obesity).

    Time frame: 16 weeks

  6. Body Composition: Change from Baseline in Limb-to-Trunk Lean Mass Ratio

    The ratio of total limb lean soft tissue (kg) to trunk lean soft tissue (kg) derived from segmental bioelectrical impedance analysis (ACCUNIQ BC720; SELVAS Healthcare). Higher scores indicate a higher proportion of appendicular muscle relative to the trunk (better outcome).

    Time frame: 16 weeks

  7. Body Composition: Change from Baseline in Arm-to-Leg Lean Mass Ratio

    The ratio of total arm lean soft tissue (kg) to total leg lean soft tissue (kg) derived from segmental bioelectrical impedance analysis (ACCUNIQ BC720; SELVAS Healthcare). Higher scores indicate greater upper limb muscle mass relative to lower limb mass.

    Time frame: 16 weeks

  8. HRQoL: Change from Baseline in EORTC QLQ-C30 Score

    Quality of life measured by the EORTC QLQ-C30; raw scores are transformed to a standardized 0-100 scale. For Global Health Status and Functional scales, higher scores indicate better quality of life/functioning (better outcome). For Symptom scales/items, higher scores indicate a higher level of symptomatology/problems (worse outcome).

    Time frame: 16 weeks

  9. HRQoL: Change from Baseline in EORTC QLQ-BR45 Score

    Breast cancer-specific quality of life measured by the EORTC QLQ-BR45; raw scores are transformed to a standardized 0-100 scale. For Functional scales (e.g., Body Image, Sexual Functioning), higher scores indicate a higher/healthier level of functioning (better outcome). For Symptom scales/items (e.g., Systemic Therapy Side Effects, Arm Symptoms), higher scores indicate a higher level of symptomatology/problems (worse outcome).

    Time frame: 16 weeks

  10. HRQoL: Change from Baseline in SarQoL Score

    Sarcopenia-specific quality of life measured by the SarQoL questionnaire; composite score transformed to a 0-100 scale. Higher scores indicate a better quality of life (better outcome).

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in this article will be available to researchers who provide a methodologically sound proposal. Proposals may be submitted beginning 9 months and ending 36 months following article publication to the corresponding author. Data will be shared after approval of the proposal and the signing of a data access agreement.

Supporting information: Study protocol, Informed consent form

Time frame: Data will become available 6 months after the primary manuscript is published in a peer-reviewed journal and will remain available for a period of 5 years.

Access criteria: Data will be shared with qualified academic researchers who provide a methodologically sound proposal. Proposals must be approved by the lead investigator's Institutional Review Board (IRB) or Ethics Committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Apr 2027, 15 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 15 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2026
First posted
Mar 11, 2026
StartActual
Jan 5, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07465393
Lead sponsor
Valeria Chiu
Responsible party
Valeria Chiu (Attending Physician, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation) — Sponsor-investigator
First posted
Mar 11, 2026
Start date
Jan 5, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Mar 12, 2026

Study contacts

Valeria Chiu
Contact
haydenbell28@gmail.com
+886266289779 ext. 67702

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion